Bank of America Issues Pessimistic Forecast for Bristol Myers Squibb (NYSE:BMY) Stock Price

Posted by Geri Gentry on Jul 10th, 2026

Bristol Myers Squibb (NYSE:BMY – Get Free Report) had its price objective decreased by research analysts at Bank of America from $67.00 to $66.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price target indicates a potential upside of 15.23% from the company’s current price.

Several other research firms have also issued reports on BMY. HSBC raised their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Guggenheim restated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $54.00 target price on shares of Bristol Myers Squibb in a research report on Monday. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average target price of $61.25.

Read Our Latest Report on BMY

Bristol Myers Squibb Trading Down 1.1%

BMY traded down $0.67 during midday trading on Friday, hitting $57.27. 3,067,672 shares of the company were exchanged, compared to its average volume of 12,298,191. The firm has a market capitalization of $116.96 billion, a P/E ratio of 16.09, a P/E/G ratio of 0.16 and a beta of 0.23. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89. The firm’s 50 day moving average price is $56.83 and its 200-day moving average price is $57.62. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts forecast that Bristol Myers Squibb will post 6.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Investment Management Company LLC raised its holdings in shares of Bristol Myers Squibb by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after purchasing an additional 172 shares during the period. KCM Investment Advisors LLC grew its stake in Bristol Myers Squibb by 0.8% during the fourth quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock valued at $1,126,000 after acquiring an additional 174 shares in the last quarter. Sandy Cove Advisors LLC increased its holdings in shares of Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after purchasing an additional 176 shares during the period. Investment Research Partners LLC raised its position in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after buying an additional 179 shares in the last quarter. Finally, ESG Planning DBA Harper Investing boosted its stake in Bristol Myers Squibb by 1.3% during the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock valued at $745,000 after buying an additional 180 shares during the period. Institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

(Get Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.